Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
YC Cohen, H Magen, M Gatt, M Sebag… - … England Journal of …, 2025 - Mass Medical Soc
Background Talquetamab (anti–G protein–coupled receptor family C group 5 member D)
and teclistamab (anti–B-cell maturation antigen) are bispecific antibodies that activate T …
and teclistamab (anti–B-cell maturation antigen) are bispecific antibodies that activate T …
Practical insights into bispecific antibody therapy in multiple myeloma
Y Kawasaki, S Winger, N Esteghamat… - Expert Review of …, 2024 - Taylor & Francis
Introduction The rise of recent novel therapies teclistamab, elranatamab, and talquetamab
for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area …
for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area …
Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
DA Moustafa, L Shafei, R Sulaiman… - Journal of Oncology …, 2024 - journals.sagepub.com
Introduction Several meta-analyses (MAs) of the efficacy and safety of daratumumab in
refractory/relapsed multiple myeloma (RRMM) exist. They include different types of …
refractory/relapsed multiple myeloma (RRMM) exist. They include different types of …
Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A …
J Yang, N Boytsov, JJ Carlson, D Barthold - Journal of Managed Care & …, 2023 - jmcp.org
BACKGROUND: Despite recent advancements in the therapeutic landscape, multiple
myeloma (MM) remains incurable. There are multiple treatment options available with a …
myeloma (MM) remains incurable. There are multiple treatment options available with a …
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
LJ Costa, TW LeBlanc, H Tesch, P Sonneveld… - Future …, 2024 - Taylor & Francis
Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359)
was compared with that of physician's choice of treatment (PCT) for triple-class refractory …
was compared with that of physician's choice of treatment (PCT) for triple-class refractory …
Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world …
Ide‐cel received approval for relapsed–refractory multiple myeloma based on the results of
the KarMMa‐1 trial. However, patients with significant comorbidities, aggressive disease …
the KarMMa‐1 trial. However, patients with significant comorbidities, aggressive disease …
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the …
Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-
center retrospective cohort study used the Canadian Myeloma Research Group Database to …
center retrospective cohort study used the Canadian Myeloma Research Group Database to …
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis
S Iida, Y Yasutomi, Y Samyshkin, YC Chen, CC Chen… - Plos one, 2025 - journals.plos.org
Background Approval of proteasome inhibitors, immunomodulatory drugs, and anti-CD38
monoclonal antibodies (mAbs), such as daratumumab, has reshaped treatment patterns in …
monoclonal antibodies (mAbs), such as daratumumab, has reshaped treatment patterns in …
Symptom experience of patients undergoing treatment for multiple myeloma: a longitudinal real-world electronic patient-reported outcomes study
MN Patel, A Nina, B Branchaud, KW Herring… - Supportive Care in …, 2024 - Springer
Purpose Patients with multiple myeloma (MM) experience significant symptom burden. We
used a symptom monitoring app to longitudinally characterize the MM treatment experience …
used a symptom monitoring app to longitudinally characterize the MM treatment experience …
Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey
Y Yasutomi, A Ribbands, E Luke, S McNamara - Future Oncology, 2025 - Taylor & Francis
Aim Multiple myeloma (MM) is a hematological malignancy associated with poor health-
related quality of life (HRQoL). Safe and effective treatments for MM are limited. There is a …
related quality of life (HRQoL). Safe and effective treatments for MM are limited. There is a …